g, general and administrative45,75940,075172,794147,057Research and development14,90912,76155,46953,098Amortization of intangibles7708753,2403,447Acquisition related items1,858-1,858-Total operating expenses63,29653,711233,361203,602Operating income5,0638,67919,59025,411Interest income246207902908Interest expense(2,982)(1,212)(7,975)(7,107)Exchange rate (loss) gain(257)184(576)(997)Loss from debt extinguishment(4,969)-(4,969)-Other, net2,749(110)2,717(112)Income (loss) before income tax(151)7,7489,68918,103Income tax expense (benefit)(2,628)(21,674)1,667(19,990)Net income$
2,477$
29,422$
8,022$
38,093Net income per share:Basic$
0.05$
0.56$
0.15$
0.73Diluted$
0.04$
0.54$
0.15$
0.70Shares used in calculating net income per share:Basic53,92452,63453,47552,300Diluted55,37154,45955,19554,596 VOLCANO CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(unaudited)Year EndedDecember 31,20122011Operating activitiesNet income
$
8,022$
38,093Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization23,50323,214Amortization (accretion) of investment premium (discount), net3,2563,805Accretion of debt discount on convertible senior notes5,7434,668Loss on debt extinguishment4,969-Acquisition related items231Non-cash stock-based compensation expense15,07912,991Other non-cash adjustments907(2,350)Deferred income taxes1,009(22,771)Changes in operating assets and liabilities(12,901)(14,054)Net cash provided by operating activities49,81843,596Investing activitiesPurchase of short-term and long-term available-for-sale investments(298,260)(310,573)Sale or maturity of short-term and long-term available-for-sale securities252,937365,639Capital expenditures(43,842)(43,248)Cash paid for acquisitions, net of cash acquired(54,462)-Cash paid for other intangible assets and investments(5
'/>"/>
SOURCE Volcano Corporation Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related medicine technology :1.
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast2.
Volcano Corporation Prices Offering Of $400 Million 1.75% Convertible Senior Notes Due 20173.
Volcano Corporation To Offer $350 Million Convertible Senior Notes Due 20174.
Volcano Corporation Signs Agreement to Acquire Sync-Rx Ltd.5.
Volcano Corporation Presentation At Piper Jaffray Conference To Be Webcast6.
Fish & Richardson Prevails in Patent Infringement Trial for Volcano Corporation7.
Volcano Corporation Schedules Third Quarter Conference Call, Webcast8.
Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical9.
Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast10.
FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial11.
Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast